211 related articles for article (PubMed ID: 24000284)
1. Early Pseudoprogression following Chemoradiotherapy in Glioblastoma Patients: The Value of RANO Evaluation.
Linhares P; Carvalho B; Figueiredo R; Reis RM; Vaz R
J Oncol; 2013; 2013():690585. PubMed ID: 24000284
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of pseudoprogression in patients with glioblastoma.
Kucharczyk MJ; Parpia S; Whitton A; Greenspoon JN
Neurooncol Pract; 2017 Jun; 4(2):120-134. PubMed ID: 31386017
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.
Nasseri M; Gahramanov S; Netto JP; Fu R; Muldoon LL; Varallyay C; Hamilton BE; Neuwelt EA
Neuro Oncol; 2014 Aug; 16(8):1146-54. PubMed ID: 24523362
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Sanghera P; Perry J; Sahgal A; Symons S; Aviv R; Morrison M; Lam K; Davey P; Tsao MN
Can J Neurol Sci; 2010 Jan; 37(1):36-42. PubMed ID: 20169771
[TBL] [Abstract][Full Text] [Related]
5. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
6. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
Moon HH; Kim HS; Park JE; Kim YH; Kim JH
BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
[TBL] [Abstract][Full Text] [Related]
7. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
9. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
[TBL] [Abstract][Full Text] [Related]
10. Defining pseudoprogression in glioblastoma multiforme.
Van Mieghem E; Wozniak A; Geussens Y; Menten J; De Vleeschouwer S; Van Calenbergh F; Sciot R; Van Gool S; Bechter OE; Demaerel P; Wilms G; Clement PM
Eur J Neurol; 2013 Oct; 20(10):1335-41. PubMed ID: 23679051
[TBL] [Abstract][Full Text] [Related]
11. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.
Huang RY; Rahman R; Ballman KV; Felten SJ; Anderson SK; Ellingson BM; Nayak L; Lee EQ; Abrey LE; Galanis E; Reardon DA; Pope WB; Cloughesy TF; Wen PY
Clin Cancer Res; 2016 Feb; 22(3):575-81. PubMed ID: 26490307
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.
Youssef G; Rahman R; Bay C; Wang W; Lim-Fat MJ; Arnaout O; Bi WL; Cagney DN; Chang YS; Cloughesy TF; DeSalvo M; Ellingson BM; Flood TF; Gerstner ER; Gonzalez Castro LN; Guenette JP; Kim AE; Lee EQ; McFaline-Figueroa JR; Potter CA; Reardon DA; Huang RY; Wen PY
J Clin Oncol; 2023 Jun; 41(17):3160-3171. PubMed ID: 37027809
[TBL] [Abstract][Full Text] [Related]
13. The Neurologic Assessment in Neuro-Oncology (NANO) Scale as an Assessment Tool for Survival in Patients With Primary Glioblastoma.
Ung TH; Ney DE; Damek D; Rusthoven CG; Youssef AS; Lillehei KO; Ormond DR
Neurosurgery; 2019 Mar; 84(3):687-695. PubMed ID: 29618103
[TBL] [Abstract][Full Text] [Related]
14. Cancer genetic markers according to radiotherapeutic response in patients with primary glioblastoma - Radiogenomic approach for precision medicine.
Yang K; Jung SW; Shin H; Lim DH; Lee JI; Kong DS; Seol HJ; Kim ST; Nam DH
Radiother Oncol; 2019 Feb; 131():66-74. PubMed ID: 30773189
[TBL] [Abstract][Full Text] [Related]
15. In silico study of pseudoprogression in glioblastoma: collaboration of radiologists and radiation oncologists in the estimation of extent of high dose RT region.
Belanova R; Sprlakova-Pukova A; Standara M; Janu E; Koukalova R; Kristek J; Burkon P; Kolouskova I; Prochazka T; Pospisil P; Chakravarti A; Slampa P; Slaby O; Kazda T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Sep; 164(3):307-313. PubMed ID: 31544900
[TBL] [Abstract][Full Text] [Related]
16. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients.
Pouleau HB; Sadeghi N; Balériaux D; Mélot C; De Witte O; Lefranc F
Int J Oncol; 2012 Apr; 40(4):923-8. PubMed ID: 22086066
[TBL] [Abstract][Full Text] [Related]
17. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
[TBL] [Abstract][Full Text] [Related]
18. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Gállego Pérez-Larraya J; Lahutte M; Petrirena G; Reyes-Botero G; González-Aguilar A; Houillier C; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Neuro Oncol; 2012 May; 14(5):667-73. PubMed ID: 22492961
[TBL] [Abstract][Full Text] [Related]
19. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
Chinot OL; Macdonald DR; Abrey LE; Zahlmann G; Kerloëguen Y; Cloughesy TF
Curr Neurol Neurosci Rep; 2013 May; 13(5):347. PubMed ID: 23529375
[TBL] [Abstract][Full Text] [Related]
20. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]